Earlier this week Health Canada announced in a press release that it has completed its re-evaluations of the neonicotinoid pesticides clothianidin, imidacloprid and thiamethoxam in relation to their potential impact on bees and other pollinators, and has released the final decisions for each.
According to Health Canada, the scientific assessments show varying effects on bees and other pollinators from exposure to each of these pesticides. To protect bees and other pollinators, Health Canada has announced that it will be cancelling some uses of these pesticides, and changing other conditions of use such as restricting the timing of application. Remaining uses (e.g., treatment on canola seeds and greenhouse vegetables) are not expected to pose unacceptable risks to bees and other pollinators.
In Canada, all pesticides must undergo a rigorous, science-based review before being approved for sale. Health Canada also regularly re-evaluates pesticides to make sure that they continue to meet modern health and safety standards.
In 2012, Health Canada began re-evaluations of three neonicotinoids to address growing concerns around bee health. The Department issued proposed decisions for clothianidin, imidacloprid and thiamethoxam in December 2017, May 2018 and December 2017, respectively, and consulted the public and stakeholders. All comments and information received during the consultation periods were considered and helped inform the final decisions.
These pollinator re-evaluations considered hundreds of scientific studies, from both manufacturers and published literature. Cancellations and new restrictions will be implemented over a two- to three-year period, in accordance with the Department’s Policy on Cancellations and Amendments Following Re-evaluation and Special Review.
The Department continues to evaluate the potential risks to aquatic insects from the use of neonicotinoids. Current research shows that these pesticides are detected frequently in waterbodies at levels that could be harmful to certain aquatic organisms. The Department expects to report on its findings at the end of 2019.
You will find the press release and related information on Health Canada’s website here